Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.
Neoplasms
DRUG: BMS-907351 (XL184)
To establish the MTD and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors, Within the first 28 days
To assess the safety and tolerability of multiple doses of BMS-907351 (XL184) administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors, Day 1, 2, 5, 8, 15, 19, 20, 29 and every 2 weeks thereafter|To assess plasma pharmacokinetics (PK) of oral administration of BMS-907351 (XL184) and the metabolite(s) in subjects with advanced or metastatic solid tumors, Day 1, 5, 15, 19 and 29|To assess tumor response (preliminary anti-tumor activity) after repeated administration of BMS-907351 (XL184), Every 8 weeks|To assess the pharmacodynamic correlates of BMS-907351 (XL184) activity, Day 1, 5, 15, 19, 29 and every 4 weeks thereafter
The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.